Subject Index

Volume 69

aflatoxin B₁, methyl-deficient diet, rat liver, serum enzymes, necrosis, lipidosis, 93

alpha-antitrypsin, rat intestinal tumors, azoxymethane, chemoprevention, 39

amino acids alcohols, differentiation, growth inhibition, melanoma, 203

animal lectins, cell-cycle kinetics, gene expression, 67

anticancer effect, polyamine uptake, spermidine, spermine, ornithine decarboxylase, S-adenosylmethionine decarboxylase, α-difluoromethylornithine, L1210 leukemia, 33

antigen, sarcoma, purification, sarcoma antigen, 173

antisense, neu, oncogene, neuroblastoma, 27

autochthonous murine mammary tumors, MMTV, enterovirus, immune tolerance, cyclophosphamide, host control of cancer, 133

azoxymethane, alpha-antitrypsin, rat intestinal tumors, chemo-Prevention, 39

basement membrane, invasion, human assay, extracellular matrix, 123

benzoyl peroxide, biomimetic superoxide dismutase, promotion, progression, skin tumors, 167

bile acids, deoxycholate, colon tumor cell differentiation, 181 biomimetic superoxide dismutase, benzoyl peroxide, promotion, progression, skin tumors, 167

bleomycin, electrotherapy, fibrosarcoma experimental, 81 breast cyst fluid, cathepsin D, pS2, oestradiol, 21

c-Ha-ras, oncogene product, protease inhibitor, cathepsin, 161 cancer risk assessment, pharmacokinetics, physiological models, metabolism, tissue binding, tissue reactivity, chemical carcinogenesis, pharmacodynamics, tissue dosimetry, sensitivity analysis, 1

carcinogenesis, green tea, catechins, tumor promotion, gap junctions, chemoprevention, 15

catechins, green tea, tumor promotion, carcinogenesis, gap junctions, chemoprevention, 15

cathepsin D, pS2, oestradiol, breast cyst fluid, 21

cathepsin, c-Ha-ras, oncogene product, protease inhibitor, 161 cell-cycle kinetics, animal lectins, gene expression, 67

chemical carcinogenesis, glutathione levels, Saraka asoca, (-)-epicatechin, 45

chemical carcinogenesis, pharmacokinetics, physiological models, metabolism, tissue binding, tissue reactivity, cancer risk assessment, pharmacodynamics, tissue dosimetry, sensitivity analysis, 1 chemoprevention, alpha-antitrypsin, rat intestinal tumors, azoxymethane, 39

chemoprevention, green tea, catechins, tumor promotion, carcinogenesis, gap junctions, 15

colon tumor cell differentiation, bile acids, deoxycholate, 181 colony formation, vinblastine, TN-16, renal carcinoma cells, soybean trypsin inhibitor, in vitro invasion assay, 85

cotinine, urine mutagenicity, tobacco habits, 75

cyclophosphamide, autochthonous murine mammary tumors, MMTV, enterovirus, immune tolerance, host control of cancer, 133

cyclosporin A, P-glycoprotein, *mdr* genes, natural killer cells, multiple drug resistance, 139

cytochrome P-450, methylbutylnitrosamine, nitrosamine, esophagus, liver microsomes, monoclonal antibody, 107 cytokines, heparin, transformation, soft agar, 197

deoxycholate, bile acids, colon tumor cell differentiation, 181 diagnostics of cancer, fluorescent dyes, induced tumors, human gastric cancer, 117

dietary fat, transgenic mice, oncogene amplification, hypomethylation, 59

differentiation, amino acids alcohols, growth inhibition, melanoma, 203

α-difluoromethylornithine, polyamine uptake, spermidine, spermine, ornithine decarboxylase, S-adenosylmethionine decarboxylase, L1210 leukemia, anticancer effect, 33

electrotherapy, bleomycin, fibrosarcoma experimental, 81 enterovirus, autochthonous murine mammary tumors, MMTV, immune tolerance, cyclophosphamide, host control of cancer, 133

(-)-epicatechin, chemical carcinogenesis, glutathione levels, Saraka asoca, 45

esophagus, methylbutylnitrosamine, nitrosamine, liver microsomes, cytochrome P-450, monoclonal antibody, 107

extracellular matrix, invasion, human assay, basement membrane, 123

fibrosarcoma experimental, bleomycin, electrotherapy, 81 fluorescent dyes, induced tumors, human gastric cancer, diagnostics of cancer, 117

gap junctions, green tea, catechins, tumor promotion, carcinogenesis, chemoprevention, 15

gene expression, animal lectins, cell-cycle kinetics, 67

glutathione levels, chemical carcinogenesis, Saraka asoca, (-)-epicatechin, 45

granulocyte-macrophage colony stimulating factor, transferrin, insulin, myeloid leukemia, receptor trafficking, hyperosmolar medium, 51

green tea, catechins, tumor promotion, carcinogenesis, gap junctions, chemoprevention, 15

growth inhibition, amino acids alcohols, differentiation, melanoma, 203

heparin, cytokines, transformation, soft agar, 197

host control of cancer, autochthonous murine mammary tumors, MMTV, enterovirus, immune tolerance, cyclophosphamide, 133

human assay, invasion, extracellular matrix, basement membrane, 123

human gastric cancer, fluorescent dyes, induced tumors, diagnostics of cancer, 117

hyperosmolar medium, transferrin, insulin, granulocytemacrophage colony stimulating factor, myeloid leukemia, receptor trafficking, 51

hypomethylation, dietary fat, transgenic mice, oncogene amplification, 59

IM-9 cells, interleukin-2, polyphenols, Molt-4, 191

immune tolerance, autochthonous murine mammary tumors, MMTV, enterovirus, cyclophosphamide, host control of cancer, 133

immunohistochemistry, sequencing, p53, pancreatic cancer, 151

in vitro invasion assay, vinblastine, TN-16, renal carcinoma cells, soybean trypsin inhibitor, colony formation, 85

induced tumors, fluorescent dyes, human gastric cancer, diagnostics of cancer, 117

insulin, transferrin, granulocyte-macrophage colony stimulating factor, myeloid leukemia, receptor trafficking, hyperosmolar medium, 51

interleukin-2, polyphenols, Molt-4, IM-9 cells, 191

invasion, human assay, extracellular matrix, basement membrane, 123

L1210 leukemia, polyamine uptake, spermidine, spermine, ornithine decarboxylase, S-adenosylmethionine decarboxylase, α-difluoromethylornithine, anticancer effect, 33

lipidosis, aflatoxin B₁, methyl-deficient diet, rat liver, serum enzymes, necrosis, 93

liver microsomes, methylbutylnitrosamine, nitrosamine, esophagus, cytochrome P-450, monoclonal antibody, 107

mammary tumor, thymosin α_1 , 187

mdr genes, P-glycoprotein, natural killer cells, multiple drug resistance, cyclosporin A, 139

melanoma, amino acids alcohols, differentiation, growth inhibition, 203

metabolism, pharmacokinetics, physiological models, tissue binding, tissue reactivity, chemical carcinogenesis, cancer risk assessment, pharmacodynamics, tissue dosimetry, sensitivity analysis, 1 methyl-deficient diet, aflatoxin B₁, rat liver, serum enzymes, necrosis, lipidosis, 93

methylbutylnitrosamine, nitrosamine, esophagus, liver microsomes, cytochrome P-450, monoclonal antibody, 107

MMTV, autochthonous murine mammary tumors, enterovirus, immune tolerance, cyclophosphamide, host control of cancer, 133

Molt-4, interleukin-2, polyphenols, IM-9 cells, 191

monoclonal antibody, methylbutylnitrosamine, nitrosamine, esophagus, liver microsomes, cytochrome P-450, 107

multiple drug resistance, P-glycoprotein, *mdr* genes, natural killer cells, cyclosporin A, 139

myeloid leukemia, transferrin, insulin, granulocyte-macrophage colony stimulating factor, receptor trafficking, hyperosmolar medium, 51

natural killer cells, P-glycoprotein, mdr genes, multiple drug resistance, cyclosporin A, 139

necrosis, aflatoxin B₁, methyl-deficient diet, rat liver, serum enzymes, lipidosis, 93

neu, antisense, oncogene, neuroblastoma, 27

neuroblastoma, neu, antisense, oncogene, 27

nitrosamine, methylbutylnitrosamine, esophagus, liver microsomes, cytochrome P-450, monoclonal antibody, 107

oestradiol, cathepsin D, pS2, breast cyst fluid, 21

oncogene amplification, dietary fat, transgenic mice, hypomethylation, 59

oncogene product, c-Ha-ras, protease inhibitor, cathepsin, 161 oncogene, neu, antisense, neuroblastoma, 27

ornithine decarboxylase, polyamine uptake, spermidine, spermine, S-adenosylmethionine decarboxylase, α-difluoromethylornithine, L1210 leukemia, anticancer effect, 33

P-glycoprotein, *mdr* genes, natural killer cells, multiple drug resistance, cyclosporin A, 139

p53, immunohistochemistry, sequencing, pancreatic cancer,

pancreatic cancer, immunohistochemistry, sequencing, p53, 151

pharmacodynamics, pharmacokinetics, physiological models, metabolism, tissue binding, tissue reactivity, chemical carcinogenesis, cancer risk assessment, tissue dosimetry, sensitivity analysis, 1

pharmacokinetics, physiological models, metabolism, tissue binding, tissue reactivity, chemical carcinogenesis, cancer risk assessment, pharmacodynamics, tissue dosimetry, sensitivity analysis, 1

physiological models, pharmacokinetics, metabolism, tissue binding, tissue reactivity, chemical carcinogenesis, cancer risk assessment, pharmacodynamics, tissue dosimetry, sensitivity analysis, 1

polyamine uptake, spermidine, spermine, ornithine decarboxylase, S-adenosylmethionine decarboxylase, α -difluoromethylornithine, L1210 leukemia, anticancer effect, 33

polyphenols, interleukin-2, Molt-4, IM-9 cells, 191

progression, benzoyl peroxide, biomimetic superoxide dismutase, promotion, skin tumors, 167 promotion, benzoyl peroxide, biomimetic superoxide dismutase, progression, skin tumors, 167

protease inhibitor, c-Ha-ras, oncogene product, cathepsin, 161 pS2, cathepsin D, oestradiol, breast cyst fluid, 21

purification, sarcoma, antigen, sarcoma antigen, 173

rat intestinal tumors, alpha-antitrypsin, azoxymethane, chemoprevention, 39

rat liver, aflatoxin B₁, methyl-deficient diet, serum enzymes, necrosis, lipidosis, 93

receptor trafficking, transferrin, insulin, granulocyte-macrophage colony stimulating factor, myeloid leukemia, hyperosmolar medium, 51

renal carcinoma cells, vinblastine, TN-16, soybean trypsin inhibitor, in vitro invasion assay, colony formation, 85

S-adenosylmethionine decarboxylase, polyamine uptake, spermidine, spermine, ornithine decarboxylase, α -difluoromethylornithine, L1210 leukemia, anticancer effect, 33

Saraka asoca, chemical carcinogenesis, glutathione levels, (-)-epicatechin, 45

sarcoma antigen, sarcoma, antigen, purification, 173 sarcoma, antigen, purification, sarcoma antigen, 173

sensitivity analysis, pharmacokinetics, physiological models, metabolism, tissue binding, tissue reactivity, chemical carcinogenesis, cancer risk assessment, pharmacodynamics, tissue dosimetry, 1

sequencing, immunohistochemistry, p53, pancreatic cancer,

serum enzymes, aflatoxin B_1 , methyl-deficient diet, rat liver, necrosis, lipidosis, 93

skin tumors, benzoyl peroxide, biomimetic superoxide dismutase, promotion, progression, 167

soft agar, heparin, cytokines, transformation, 197

soybean trypsin inhibitor, vinblastine, TN-16, renal carcinoma cells, in vitro invasion assay, colony formation, 85

spermidine, polyamine uptake, spermine, ornithine decarboxylase, S-adenosylmethionine decarboxylase, α -difluoromethylornithine, L1210 leukemia, anticancer effect, 33

spermine, polyamine uptake, spermidine, ornithine decarboxylase, S-adenosylmethionine decarboxylase, α -difluoromethylornithine, L1210 leukemia, anticancer effect, 33

thymosin α_1 , mammary tumor, 187

tissue binding, pharmacokinetics, physiological models, metabolism, tissue reactivity, chemical carcinogenesis, cancer risk assessment, pharmacodynamics, tissue dosimetry, sensitivity analysis. 1

tissue dosimetry, pharmacokinetics, physiological models, metabolism, tissue binding, tissue reactivity, chemical carcinogenesis, cancer risk assessment, pharmacodynamics, sensitivity analysis, 1

tissue reactivity, pharmacokinetics, physiological models, metabolism, tissue binding, chemical carcinogenesis, cancer risk assessment, pharmacodynamics, tissue dosimetry, sensitivity analysis, 1

TN-16, vinblastine, renal carcinoma cells, soybean trypsin inhibitor, in vitro invasion assay, colony formation, 85

tobacco habits, cotinine, urine mutagenicity, 75

transferrin, insulin, granulocyte-macrophage colony stimulating factor, myeloid leukemia, receptor trafficking, hyperosmolar medium, 51

transformation, heparin, cytokines, soft agar, 197

transgenic mice, dietary fat, oncogene amplification, hypomethylation, 59

tumor promotion, green tea, catechins, carcinogenesis, gap junctions, chemoprevention, 15

urine mutagenicity, cotinine, tobacco habits, 75

vinblastine, TN-16, renal carcinoma cells, soybean trypsin inhibitor, in vitro invasion assay, colony formation, 85



Author Index Volume 69

Akin, C.	51	Hiwasa, T.	161
Andersen, M.E.	1	Huang, Q.	107
Ask, A.	33	Hurst, R.E.	197
Askew, D.	67		
		Igawa, T.	85
Babcook, D.M.	107		
Barsoum, A.L.	187	Kanda, S.	85
Beger, H.G.	151	Kanetake, H.	85
Bhisey, R.A.	75	Kaufman, D.G.	123
Biggs, M.W.	133	Kawamura, M.	85
Braginskaja, O.V.	117	Kennedy, J.W.	123
Buchler, M.	151	Kobrin, M.S.	151
Burger, C.J.	67	Koide, H.	161
Bynum, R.L.	197	Korc, M.	151
		Krewski, D.	1
Campbell, J.S.	93	Kurl, R.N.	187
Casey, G.	151		
Chang, SH.	27	Lai, L.C.	21
Chang, WC.	27	Lai, MD.	27
Chen, S.C.	107	Landau, O.	203
Chiou, ST.	27	Lanfranchi, H.	167
Cornell, C.	21	Laver, G.W.	93
		Lazarev, V.V.	117
Das, N.P.	191	Lennard, T.W.J.	21
Desai, T.K.	181	Lopez, M.E.	151
Deutsch, A.A.	203	=	
Devi, M.A.	191	Mehta, R.	93
Durán, H.A.	167	Miklavcic, D.	81
Duran, 11.71.		Miller, Y.	123
Eiselein, J.E.	133	Mirvish, S.S.	107
Elgert, K.D.	67	Morin, M.J.	181
Ligert, K.D.	0,	Mueller, R.	93
Farmer, S.J.	59		
Feit, C.	173	Nair, S.C.	45
Friess, H.	151	Nakamura, M.	85
Fujita-Yoshigaki, J.	161	Nathan, D.F.	181
i ujita 1 osingani, v.		Naylor, P.H.	187
Gekeler, V.	139	Niethammer, D.	139
Gelboin, H.V.	107	Noller, A.	139
Ghose, T.	39	Nordenberg, J.	203
Goodly, L.J.	123	Novakovic, S.	81
Govekar, R.B.	75	Novogrodsky, A.	203
Gupta, N.K.	173		
Oupla, N.K.	1/3	Nüssler, V.	139
Handgretinger, R.	139	Palmieri, M.A.	167
Heby, O.	33	Panet, H.	203
Hirshaut, Y.	173	Panikkar, B.	45

Panikkar, K.R.	45	Siegal, G.P.	123
Park, S.S.	107	Sigler, K.	15
Perrson, L.	33	Singh, R.K.	123
Polsachev, V.I.	117	Sonnenfeld, G.	51
Probst, H.	139	Stapley, R.	93
		Steinmeyer, C.	59
Reddy, B.S.	39	Stoskii, V.E.	117
Reiss, R.	203		
de Rey, B.M.	167	Varghese, C.D.	45
Rhodes, S.W.	197	varghese, c.b.	43
Rijhsinghani, K.	39		59
Rinehart, C.A.	123	Waddell, K.	123
Rubin, L.B.	117	Wang, MH.	107
Ruch, R.J.	15	Wang, S.	
		Wasserman, L.	203
Saito, Y.	85	Weger, S.	139
Sakiyama, S.	161	Wilisch, A.	139
Sawada, T.	161		
Schmall, B.	173	De Wille, J.W.	59
Seiler, N.	33	Withey, J.R.	1
Sersa, G.	81		
Shaw, YT.	27	Yamanaka, Y.	151
Shirouzu, M.	161	Yokoyama, S.	161

